Develops therapies for neurological and kidney diseases.
DiaMedica Therapeutics Inc., headquartered in Minneapolis, Minnesota, is a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological and kidney diseases. At the forefront of its development efforts is DM199, a recombinant human tissue kallikrein-1 protein. This lead drug candidate is currently undergoing Phase 2 trials in the REDUX study for patients with moderate or severe chronic kidney disease stemming from Type I or Type II diabetes. Additionally, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for its potential to treat patients with acute ischemic stroke, highlighting DiaMedica's commitment to addressing critical medical needs through innovative therapeutic approaches.
In addition to DM199, DiaMedica Therapeutics is actively advancing DM300, a promising candidate in the pre-clinical stage. DM300 aims to target inflammatory diseases, expanding the company's therapeutic pipeline to address broader health challenges beyond its current focus areas. Formerly known as DiaMedica Inc., the company rebranded as DiaMedica Therapeutics Inc. in December 2016, reflecting its strategic evolution and commitment to therapeutic innovation over its two-decade history since incorporation in 2000.
DiaMedica Therapeutics continues to leverage its expertise in biopharmaceutical research and development to pioneer novel treatments that aim to improve patient outcomes and quality of life. With a robust pipeline and a focus on advancing therapies for complex diseases, DiaMedica Therapeutics remains dedicated to making significant contributions to the field of medical science and enhancing healthcare solutions worldwide.